• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Emergent BioSolutions

    Adare Pharma Solutions

    Syngene

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Emergent BioSolutions

    Almac Group

    Alcami

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Oral Solids Endure & Evolve

    Contract Pharma talks with several contract service providers about the state of the oral solid dose development and manufacturing market.

    Oral Solids Endure & Evolve
    Related CONTENT
    • Alcami
    • PCI Pharma Services
    • Reed-Lane
    • Vetio Animal Health
    • Are We Embracing FDA’s Messages?
    Tim Wright, Editor, Contract Pharma03.06.19
    The oral solid dose (OSD) development through manufacturing pipeline of products is expanding at a robust rate—even while industry watches the investment, interest and demand for biologics and biosimilars growing rapidly. There are several reasons OSDs continue to be the most popular dosage form for getting drugs to patients. In addition to being cost effective and relatively easy to make compared to their large molecule counterparts, they are most importantly, patient friendly, especially among the pediatric and geriatric populations.

    Another reason they remain popular is that OSDs hold substantial opportunity in extending product lifecycles, and thereby leveraging growth potential. Manufacturers of OSDs today are employing various life cycle management patent strategies, including the development of new drug formulations such as extended, controlled, or rapid release formulations.

    Future Market Insights (FMI), in a recent report, projected the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027. In terms of revenue, the market reached nearly $500 billion in 2017 and is expected to surpass the $900 billion mark by 2027.

    While oral solid products may seem a bit unfashionable compared with the steep increase in new biopharmaceutical products, they nevertheless will continue to constitute a major share of all medicines for the foreseeable future, according to Torkel Gren, senior director, science and technology officer, Recipharm AB. “Interestingly, there is also a lot of new product development in this area,” he said. “Many of these products in development are improved formulations of existing dosage forms, such as modified or controlled release, and can offer significant advantages.”

    Michael Reel, director of technical services at Alcami said the contract development and manufacturing organization (CDMO) sees a broad range of clients in the OSD manufacturing market. “On one end of the spectrum, there are companies with extensive knowledge and experience in drug development, looking for a partner that can provide capacity,” he said. “On the other end, there are emerging organizations seeking expertise in bringing their product through the various phases and to the market. Recognizing that these companies are an innovation engine for the industry, Alcami focuses on understanding and serving them to drive change and positively impact the industry through development and launch of new treatments.”

    North America Still Largest Piece of the Pie
    In the foreseeable future, North America will remain the largest market for oral solids, followed by Asia-Pacific Excluding Japan (APEJ) and Western Europe. Revenue from the market in North America is expected to surpass $300 billion by the end of 2027, according to the FMI report. In addition, APEJ is projected to reach revenue worth $295 billion by the same time.

    In terms of dosage form, tablets will continue to remain preferred in the market, with sales estimated to climb past the $500 billion mark by 2027. Sales of tablets are anticipated to exhibit the highest CAGR in the market, ftollowed by capsules, which are expected to register 6% growth.

    Based on release mechanism, immediate release will remain dominant in the market, expanding at 6.4% CAGR through 2027. Immediate release is expected to generate revenue over $400 billion by the end of 2027. Controlled release formulations are expected to register 7.4% growth during the same time period.

    The FMI report also noted that Latin America is emerging as an important manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources. In fact, propelled by investments from multinational companies that are focusing on expanding their presence in this region, Latin America is expected to have the fastest growth pace in the market, expanding at 9.2% CAGR through 2027.

    In other growth markets, the emergence of affluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region. Consumers here are adopting western lifestyles, leading them to suffer western lifestyle-related diseases including diabetes, cancer and obesity, which is contributing to market growth in APEJ. However, factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in U.S. FDA compliance are expected to impede growth of the market in APEJ.

    OSD Growth Drivers
    Several factors are influencing the solid oral dose market, according to Justin Schroeder, senior executive director, global marketing and design, PCI Pharma Services. “Drugs are becoming increasingly targeted and specialized,” he said. “This leads to higher value medicines and creates more fragmented patient populations, impacting batch sizes and campaign volumes, in turn driving the need for increased efficiencies and more flexible equipment. At the same time, reduced scale manufacturing and packaging creates a more complex supply chain. This means that CDMOs need to look at alternative models to deliver efficiencies and remain competitive.”

    With the continued focus on quality and regulatory requirements, visible from the audit processes in which operators in today’s market are involved, supply chain assurance at every stage is driving changes in how companies operate, especially as globalization continues.

    “New markets are opening up,” Schroeder said, “providing significant opportunities for the pharmaceutical industry in terms of patient populations. The outsourcing industry therefore needs to evolve to support this growth. For companies utilizing services from the developing nations where differences in requirements may exist, careful management is needed to ensure global compliance.”

    Anil Kane, executive director, global head of technical and scientific affairs, Thermo Fisher Scientific (Patheon), highlighted the rise in development of new chemical entities (NCEs) for cancer and immune therapy as a key driver in today’s market. “The number of NCEs being evaluated for various cancers and immunotherapies has been on the rise over the past 3 years and we see this trend continuing to gain interest,” he said. “Oral solid development continues to be of interest in this therapeutic area for reasons of convenience in dosing—in adult and geriatric segments of the population—as well as for compliance. This is also evident in the number of clinical trials being conducted on a global basis.”

    As the number of NCEs coming out of drug discovery are reducing, there is an enhanced focus on exploring line extensions and life cycle management strategies. “Approved drugs with established safety profiles as well as known pharmacokinetic profiles including tolerable doses are being explored for newer indications,” said Kane. “Clinical studies in humans can be expedited since safety and tolerability of the drug is no longer an issue. Understanding the new targets and mechanism of action, followed by establishing pharmacodynamic and clinical efficacy of a new disease state or indication is a new way to bring drugs faster to the patient and to the market.”

    In addition, delivering a combination of drugs is another strategy being used. “Combining two or more established drugs is not a new life cycle management strategy, however, fixed dose combinations for a new indication offers another opportunity to use the established safety profiles of drugs and evaluate new doses for an entirely new indication,” said Kane. “We see many new organizations and start-ups exploring these opportunities to bring combination drugs to market and to patients.”

    Opportunities & Challenges
    While there is a growing interest for more specialized products often with relatively low production volumes, at the same time there is also a continued interest in new products with improved properties based on old drug substances. “Globally, there is a lot of manufacturing capacity for solid dosage forms,” said Recipharm’s Gren. “Unfortunately, a lot of this capacity was designed to suit the old ‘blockbuster’ paradigm. Today, the demand is for more flexible solid manufacturing capacity. Non-standard dosage forms, smaller batches and difficult active pharmaceutical ingredients (APIs) are examples of areas that are increasingly important. The challenge lies in being able to adapt current operations to offer more flexible manufacturing operations.”

    According to Alcami’s Reel, today’s OSD formulations are becoming more complex. “Compounds with low solubility and/or high potency demand innovative formulas to achieve the desired results,” he said. “Sustained release and controlled release formulations remain increasingly popular. Throughout the manufacturing process, sources of potential extractables and leachables must be identified.”

    There has also been a lot of focus on ensuring high and reproducible oral bioavailability of poorly soluble drug substances and, as a result, several technologies are now available to cater for these products, added Gren. “Coated pellet technology has been around for a long time, but now we are seeing a strong interest in this technology as it is useful for modified release and fixed dose combinations, as well as products that combine both these concepts,” he said. “Mini-tablets have also been around for a while but demand is growing as they are well suited to many combination products and allow for flexible dosing.”

    With many of today’s NCEs being highly potent compounds, according to Thermo Fisher’s Kane, the nature of these drugs in clinical manufacturing requires handling under containment to prevent exposure to personnel. “Processing and packaging of these high potent compounds is challenging but can be done safely using contained equipment,” he said. “Thermo Fisher has invested in the build out of engineering controls and equipment to support handling high potent compounds.”

    With the focus on oncology specifically, PCI is also supporting the development, manufacturing and packaging of many more highly potent compounds. “This is an area where we have made significant investments in both world-class technology as well as expert and experienced staff, supporting processes for total containment of drug product,” he said. “This expertise and specialization allows us to provide our clients with a seamless development-to-commercialization, or ‘molecule-to-market’, pathway with drug development, clinical and commercial scale manufacturing, clinical supply packaging and logistics, commercial launch and ongoing supply for the entirety of the drug lifecycle.”

    Moving forward, a major driver for business success is flexibility, according to Reel. “While plans are made and schedules defined before the project begins, knowledge gained as the project progresses requires adjustments to the schedule,” he said. “One of the most challenging aspects is maintaining the agility and flexibility to react to changing protocols. The ability to communicate effectively and to make adjustments rapidly and smoothly is key to bringing projects to fruition.Client requirements in early phase studies often evolve based on clinical results. This frequently means redevelopment or expansion of the dosage range covered by manufacturing. Being able to respond to changes that benefit the patient is critical to our success as a CDMO.”

    In the end, Schroeder said the outsourcing and partnership segment is flourishing. “Vendor consolidation leads to growth, in turn leading to additional investment,” he said. “As long as we continue to listen to our customers to understand exactly what they need, and invest in the best solutions, we are looking forward to continued and sustained growth.” 
    Related Searches
    • china
    • fda
    • Dosage
    • pipeline
    Suggested For You
    Alcami Alcami
    PCI Pharma Services PCI Pharma Services
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?
    Pacira Expands Exparel Mfg. Capacity Pacira Expands Exparel Mfg. Capacity
    Thermo Fisher, Torque Build Dedicated Slipstream Mfg. Facility Thermo Fisher, Torque Build Dedicated Slipstream Mfg. Facility
    Product Showcase Product Showcase
    Akorn Receives FDA Warning Letter Akorn Receives FDA Warning Letter
    Thermo Fisher Opens Shanghai Bioprocess Design Center Thermo Fisher Opens Shanghai Bioprocess Design Center
    Thermo Fisher Scientific Introduces Savant SpeedVac Systems Thermo Fisher Scientific Introduces Savant SpeedVac Systems
    Thermo Scientific Launches Orbitrap ID-X with Mass Spec Software Thermo Scientific Launches Orbitrap ID-X with Mass Spec Software
    Thermo Fisher Officially Opens New Facility Thermo Fisher Officially Opens New Facility
    Janssen Receives FDA Approval for INVOKANA Janssen Receives FDA Approval for INVOKANA
    Thermo Fisher, Symphogen Enter Collaboration Thermo Fisher, Symphogen Enter Collaboration

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Wiley’s Finest Earns Accolades for Taste of Omega-3 Products
    Clinical Evidence Suggests Potential Oral Benefits for Curcumin Extract
    Oleic Acid Possibly Implicated in MS Pathology
    Coatings World

    Latest Breaking News From Coatings World

    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    In Memoriam: CIN’s Honorary Chairman António Serrenho
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Interplex Acquires OCP Group
    FDA Clears a Portable Hemodialysis System
    Solid Growth Forecast for India's HER2 Amplification Tests Market
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Humanigen, Emergent Enter Covid-19 Partnership
    Samsung Bioepis Opens New Headquarters
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Fitglow Beauty Wins Makeup Category at Annual Dirty Thinker’s Choice Awards
    Happi

    Latest Breaking News From Happi

    Henkel Recognizes Top Suppliers
    Estée Lauder Travel Retail's Sustainability Goals
    Some Good News at Inter Parfums
    Ink World

    Latest Breaking News From Ink World

    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mat Jones joins Grafotronic
    UPM Raflatac unveils new linerless labeling product
    VPF launches deep-freeze adhesive
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Nextremity Solutions Enters Supply Agreement with Fort Wayne Metals
    osteolabs Closes Second Financing Round of Nearly 1.6 Million Euros
    First Patient Implanted With NEXXT MATRIXX SA Cervical Turn-Lock System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    Imec Technology Taking Off to Space
    North American Semiconductor Equipment Industry Posts December 2020 Billings

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login